| 供貨周期 |
一周 |
規(guī)格 |
凍干粉 |
| 應(yīng)用領(lǐng)域 |
醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
主要用途 |
科學(xué)研究 |
CRL-3006 JeKo-1 人套細(xì)胞淋巴瘤細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和*培養(yǎng)條件！
CRL-3006 JeKo-1 人套細(xì)胞淋巴瘤細(xì)胞
| ATCC® Number: | CRL-3006™ | Price: | $417.00 |
| Designations: | JeKo-1 |
|
| | Depositors: | Elias Campo |
|
| | Biosafety Level: | 1 |
|
| | Shipped: | frozen |
|
| | Medium & Serum: | See Propagation |
|
| | Growth Properties: | suspension |
|
| | Organism: | Homo sapiens (human) |
|
| | Morphology: | lymphoblast Characterization Data |
|
| | Source: | Organ: peripheral blood
Tissue: Mantle Cell Lymphoma |
|
| | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | | CRL-3006 JeKo-1 人套細(xì)胞淋巴瘤細(xì)胞 |
|
| | Antigen Expression: | CD3-, CD5+, CD10+, CD19+ (verified at ATCC ) |
|
| | DNA Profile (STR): | Amelogenin:X CSF1PO:9,12 D13S317:8,9 D16S539:12 D5S818:10,13 D7S820:10,11 THO1:7 TPOX:8 vWA: 14 |
|
| | Age: | 78 |
|
| | Gender: | female |
|
| | Comments: | The JeKo-1 Mantle cell lymphoma (MCL) cell line was established from peripheral blood mononuclear cells of a patient with a large cell variant of MCL showing leukemic conversion. JeKo-1 cells are negative for Epstein-Barr virus and express IgM, a B-cell phenotype. The cells overexpress cyclin D1, Bcl-2, c-Myc and Rb proteins. Bcl-1/J(H) gene rearrangement was confirmed by polymerase chain reaction. JeKo-1 cells are highly tumorigenic in SCID mice. [PubMed: 9753063] |
|
| | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Atmosphere: 5% CO2 in air recommended
Temperature: 37.0°C |
|
| | Subculturing: | Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 10(4) to 4 X 10(4) viable cells/ml. Do not allow the cell concentration to reach 2.5 X 10(6) cells/ml. |
|
| | Preservation: | Freeze medium: 30% RPMI; 60% FBS; 10% DMSO
Storage temperature: liquid nitrogen vapor phase |
|
| | References: | 92895: Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365
16172573: Camps, J., et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res. 30(8):923-934 (2006). PubMed: 16448697
16172575: Jeon, H.J., et al. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. ;102(5):1323-1326 (1998 ). PubMed: 9753063 |
|
|
CRL-3006
| ATCC® Number: | CRL-3006™ | Price: | $417.00 |
| Designations: | JeKo-1 |
|
| | Depositors: | Elias Campo |
|
| | Biosafety Level: | 1 |
|
| | Shipped: | frozen |
|
| | Medium & Serum: | See Propagation |
|
| | Growth Properties: | suspension |
|
| | Organism: | Homo sapiens (human) |
|
| | Morphology: | lymphoblast Characterization Data |
|
| | Source: | Organ: peripheral blood Tissue: Mantle Cell Lymphoma |
|
| | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
|
|
| | Antigen Expression: | CD3-, CD5+, CD10+, CD19+ (verified at ATCC ) |
|
| | DNA Profile (STR): | Amelogenin:X CSF1PO:9,12 D13S317:8,9 D16S539:12 D5S818:10,13 D7S820:10,11 THO1:7 TPOX:8 vWA: 14 |
|
| | Age: | 78 |
|
| | Gender: | female |
|
| | Comments: | The JeKo-1 Mantle cell lymphoma (MCL) cell line was established from peripheral blood mononuclear cells of a patient with a large cell variant of MCL showing leukemic conversion. JeKo-1 cells are negative for Epstein-Barr virus and express IgM, a B-cell phenotype. The cells overexpress cyclin D1, Bcl-2, c-Myc and Rb proteins. Bcl-1/J(H) gene rearrangement was confirmed by polymerase chain reaction. JeKo-1 cells are highly tumorigenic in SCID mice. [PubMed: 9753063] |
|
| | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%. Atmosphere: 5% CO2 in air recommended Temperature: 37.0°C |
|
| | Subculturing: | Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 10(4) to 4 X 10(4) viable cells/ml. Do not allow the cell concentration to reach 2.5 X 10(6) cells/ml. |
|
| | Preservation: | Freeze medium: 30% RPMI; 60% FBS; 10% DMSO Storage temperature: liquid nitrogen vapor phase |
|
| | References: | 92895: Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365
16172573: Camps, J., et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res. 30(8):923-934 (2006). PubMed: 16448697
16172575: Jeon, H.J., et al. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. ;102(5):1323-1326 (1998 ). PubMed: 9753063 |
|
|
15
